HCW Biologics Inc

Research HCW Biologics Inc (HCWB) on Bullrun: market cap USD 2.92M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 2.92M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 54.23K-USD 7.96M-USD 13.39M20.0%-10.63USD 1.95MUSD 6.81MUSD 2.76M
FY2024USD 2.57M-USD 30.02M-USD 14.49M37.4%-30.96USD 4.67MUSD 13.69M-USD 6.77M
FY2023USD 2.84M-USD 24.99M-USD 28.72M19.7%-0.7USD 3.60MUSD 6.42MUSD 13.46M
FY2022USD 6.72M-USD 14.90M-USD 20.66M38.5%-0.42USD 22.33MUSD 44.68MUSD 37.43M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 2.92Mn/an/an/a
20252025-12-31USD 2.62Mn/an/an/a
20242024-12-31USD 19.86Mn/an/an/a
20232023-12-29USD 44.07Mn/an/an/a
20222022-12-30USD 68.69Mn/an/an/a
20212021-12-31USD 82.98Mn/an/an/a

About HCW Biologics Inc

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is HCW Biologics Inc's market cap?

HCW Biologics Inc's market capitalization is USD 2.92M.

What does HCW Biologics Inc do?

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.